Phibro Animal Health Corporation announced the successful completion of its acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. This transaction, initially announced on April 28, 2024, marks a significant expansion for Phibro. The acquired portfolio includes more than 37 product lines.
These products are sold across approximately 80 countries and are supported by six manufacturing sites located in the U.S., Italy, and China. The acquisition also integrates a team of over 300 employees who primarily support the manufacturing and distribution activities of the business. This expansion is expected to enhance Phibro's global footprint and operational capabilities.
The company anticipates that the acquired portfolio will boost its profitability and EBITDA margin. Furthermore, the acquisition is projected to be accretive to Phibro's Adjusted Earnings Per Share, aligning with the company's strategic goals to diversify its revenue base and support future investments in animal health product categories.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.